UBS lowered the firm’s price target on Nurix Therapeutics (NRIX) to $26 from $30 and keeps a Buy rating on the shares. The firm sees asymmetric upside at the current stock price with multiple data catalysts in the next 12 months, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX: